Time course of repeated intratympanic gentamicin for Méniè re's disease

Laryngoscope

Volumn 119, Issue 4, 2009, Pages 792-798

  Nguyen, Kimanh D ^a   Minor, Lloyd B ^a   Santina, Charles C Delia ^a   Carey, John P ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

M ni re's disease; Repeated intratympanic gentamicin; Timing

Indexed keywords

GENTAMICIN; ANTIINFECTIVE AGENT;

ACCURACY; ADULT; ARTICLE; CONTROLLED STUDY; DISEASE CONTROL; DRUG DOSE TITRATION; DRUG TREATMENT FAILURE; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MENIERE DISEASE; PREDICTION; PRIORITY JOURNAL; PROBABILITY; RECURRENT DISEASE; REPEATED DRUG DOSE; VERTIGO; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; INJECTION; TREATMENT OUTCOME;

ANTI-BACTERIAL AGENTS; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; GENTAMICINS; HUMANS; INJECTIONS; KAPLAN-MEIERS ESTIMATE; MENIERE DISEASE; RECURRENCE; TREATMENT OUTCOME;

EID: 65249175616     PISSN: 0023852X     EISSN: None     Source Type: Journal    
DOI: 10.1002/lary.20055     Document Type: Article

References (22)

1. Schessel D., Minor LB, Nedzelski J. Ménière's disease and other peripheral vestibular disorders. In: Cummings CW, et al, eds. Otolaryngology-Head and Neck Surgery. 4th ed. Chicago: Mosby Year Book; 2004: 3209-3253.
2. Boleas-Aguirre MS, Lin FR, la Santina CC, Minor LB, Carey JP. Longitudinal results with intratympanic dexamethasone in the treatment of Ménière's disease. Otol Neurotol 2008; 29:33-38.
3. Lange G. Gentamicin and other ototoxic antibiotics for the transtympanic treatment of Ménière's disease. Arch Otorhinolaryngol 1989; 246:269-270.
4. Cohen-Kerem R., Kisilevsky V., Einarson TR, Kozer E., Koren G., Rutka JA. Intratympanic gentamicin for Ménière's disease: a meta-analysis. Laryngoscope 2004; 114:2085-2091.
5. Chia SH, Gamst AC, Anderson JP, Harris JP. Intratympanic gentamicin therapy for Ménière's disease: a metaanalysis. Otol Neurotol 2004; 25:544-552.
6. Quaranta A., Scaringi A., Aloidi A., Quaranta N., Salonna I. Intratympanic therapy for Ménière's disease: effect of administration of low concentration of gentamicin. Acta Otolaryngol 2001; 121:387-392.
7. Quanranta A., Aloisi A., DeBenedittis G., Scaringi A. Intratympanic therapy for Ménière's disease. High-concentration gentamicin with round-window protection. Ann NY Acad Sci 1999; 884:410-424.
8. Harner SG, Driscoll CL, Facer GW, Beatty CW, McDonald TJ. Long-term follow-up of transtympanic gentamicin for Ménière's syndrome. Otol Neurotol 2001; 22:210-214.
9. Youssef TF, Poe DS. Intratympanic gentamicin injection for the treatment of Ménière's disease. Am J Otol 1998; 19: 435-442.
10. Abou-Halawa AS, Poe DS. Efficacy of increased gentamicin concentration for intratympanic injection therapy in Ménière's disease. Otol Neurotol 2002; 23:494-502.
11. Monsell EM, Balkany TA, Gates GA, Goldenberg RA, Meyerhoff WL, House JW. Committee on hearing and equilibrium guidelines for the diagnosis and evaluation of therapy in Ménière's disease. Otalaryngol Head Neck Surg 1995; 113:181-185.
12. Minor LB. Intratympanic gentamicin for control of vertigo in Ménière's disease: vestibular signs that specify completion of therapy. Am J Otol 1999; 20:209-219.
13. Lin FR, Migliaccio AA, Haslwanter T., Minor LB, Carey JP Angular vestibulo-ocular reflex gains correlate with vertigo control after intratympanic gentamicin treatment for Ménière's disease. Ann Otol Rhinol Laryngol 2005; 114: 777-785.
14. De Beer L., Stokroos R., Kingma H. Intratympanic gentamicin therapy for intractable Ménière's disease. Acta Otolaryngol 2007; 127:605-612.
15. Bodmer D., Morong S., Stewart C., Alexander A., Chen JM, Nedzelski JM. Long-term vertigo control in patients after intratympanic gentamicin instillation for Ménière's disease. Otol Neurotol 2007; 28:1140-1144.
16. Pyykko I., Ishizaki H., Kaasinen S., Aalto H. Intratympanic gentamicin in bilateral Ménière's disease. Otolaryngol Head Neck Surg 1994; 110:162-167.
17. Hirvonen TP, Minor LB, Hullar TE, Carey JP. Effects of intratympanic gentamicin on vestibular afferents and hair cells in the chinchilla. J Neurophysiol 2005; 93:643-655.
18. Lyford-Pike S., Vogelheim C., Chu E., la Santina CC, Carey JP. Gentamicin is primarily localized in vestibular type I hair cells after intratympanic administration. J Assoc Res Otolaryngol 2007; 8:497-508.
19. Magnusson M., Padoan S. Delayed onset of ototoxic effects of gentamicin in treatment of Ménière's disease. Rationale for extremely low dose therapy. Acta Otolaryngol 1991; 111:671-676.
20. Schoendorf J., Neugebauer P., Michel O. Continuous intratympanic infusion of gentamicin via a microcatheter in Ménière's disease. Otolaryngol Head Neck Surg 2001; 124:203-207.
21. Laitakari K. Intratympanic gentamycin in severe Ménière's disease. Clin Otolaryngol Allied Sci 1990; 15:545-548.
22. Perez N., Martin E., Garcia-Tapia R. Intratympanic gentamicin for intractable Ménière's disease. Laryngoscope 2003; 113:456-464.